Progression Of Molecular Targeted Therapy For Gastric Cancer

Gastric cancer is one of the most common malignant tumor of digestive tract, and the second major cause of cancer death in the world. Because of no significant clinical symptoms of early gastric cancer and hidden alert indicator s, the early diagnosis rate is low. The vast majority of patients at the time of diagnosis has been local invasion or distant metastasis. They miss the opportunity to surgery. Chemotherapy is one of the main means for advanced gastric cancer. But combined chemotherapy doesn’t improve the treatment effect obviously. The median survival in patients with gastric cancer is between 8 and 11 months. With the researches of molecular biological mechanism of the occurrence, development, recurrence and metastasis for gastric cancer, molecular target therapy has become hot in recent years. Molecular targeted therapy restrains cancer targets effectively from molecular level. It inhibits or kills tumor cells with its unique steadiness, accuracy, malignity and reduced side effects of normal cells and tissues. Molecular targeted drugs shows good curative effect in a variety of cancers, including breast cancer, colorectal cancer, and gastrointestinal stromal tumor. C urrently, clinical researches of targeted therapy for gastric cancer mainly include: the epidermal growth factor inhibitor angiogenesis inhibitors, the epidermal growth factor inhibitors, angiogenesis inhibitors, multiple targets tyrosine kinase inhibitors, mTOR inhibitors, c-MET inhibitors, etc. O nly trastuzumab、ramucirumab and apatinib have been confirmed with significant curative effect for advanced gastric cancer in international randomized studies. The development of other targeted drugs and further researches need to focus on. The main purpose of this review is to introduce the recent development and application in gastric cancer targeted therapy drugs.